Biohaven Pharmaceutical Holding Company Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Biohaven Pharmaceutical Holding Company Ltd. generated cash of -$331,725,000, which is less than the previous year. Cash used in financing activities reached the amount of $211,908,000 last year. Net change in cash is therefore $9,516,000.
Cash Flow
| 2017 | -94.81M | -7.04M | 209.75M |
|---|---|---|---|
| 2018 | -197.14M | -10.54M | 340.46M |
| 2019 | -377.33M | -3.78M | 434.59M |
| 2020 | -75.95M | -2.69M | 152.24M |
| 2021 | -145.84M | 944K | 138.44M |
| 2022 | -297.68M | -304.79M | 767.59M |
| 2023 | -331.72M | 129.83M | 211.90M |
BHVN Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 242.60M | 77.05M | 83.50M | 9.91M | 264.24M | 131.46M | 23.56M |
Operating activities | |||||||
Net income | -408.16M | -570.27M | -213.79M | -118.66M | -528.80M | -240.92M | -127.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 6.91M | 1.38M | 1.39M | 72K | 0 | 0 | 0 |
Stock-based compensation expense | 28.78M | 193.55M | 65.63M | 29.5M | 54.97M | 16.92M | 13.23M |
| Deferred income tax benefit | 28.78M | 193.55M | 65.63M | 29.5M | 54.97M | 16.92M | 13.23M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | -188.15M | -120.11M | 0 | 0 | 0 |
Inventories | 0 | 0 | -24.10M | -37.96M | 0 | 0 | 0 |
Accounts payable | 4.87M | 5.92M | 1.02M | 222K | 3.31M | 5.39M | 3.97M |
Cash generated by operating activities | -331.72M | -297.68M | -145.84M | -75.95M | -377.33M | -197.14M | -94.81M |
Investing activities | |||||||
Purchases Of Investments | -194.12M | -263.71M | -193.29M | -319.39M | 0 | -6.37M | -6.62M |
Investments In Property Plant And Equipment | -3.04M | -41.07M | -938K | -2.69M | -2.53M | -4.16M | -541K |
Acquisitions Net | 0 | -35M | 1.88M | 267.51M | 0 | 0 | 0 |
Cash generated by investing activities | 129.83M | -304.79M | 944K | -2.69M | -3.78M | -10.54M | -7.04M |
Financing activities | |||||||
Common Stock Issued | 243.22M | 283.80M | 138.05M | 92.24M | 0 | 43.95M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -2.24M | 0 | 0 | 0 |
Cash used in financing activities | 211.90M | 767.59M | 138.44M | 152.24M | 434.59M | 340.46M | 209.75M |
Net Change In Cash | 9.51M | 165.54M | -6.44M | 73.58M | 53.47M | 132.78M | 107.90M |
Cash at end of period | 252.12M | 242.60M | 77.05M | 83.50M | 317.72M | 264.24M | 131.46M |
| Data source | Data source | Data source | Data source | Data source | Data source |